Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients

Acta Oncologica

Volumn 47, Issue 5, 2008, Pages 809-824

  Chistiakov, Dimitry A ^a,b   Voronova, Natalia V ^b   Chistiakov, Pavel A ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^c Cancer Research Center   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BINDING PROTEIN; DNA DEPENDENT PROTEIN KINASE; DNA POLYMERASE; MRE11 PROTEIN; NIBRIN; PROTEIN XRCC4; RAD50 PROTEIN;

ATAXIA TELANGIECTASIA; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DISEASE SEVERITY; DNA REPAIR; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; IMMUNE DEFICIENCY; NIJMEGEN BREAKAGE SYNDROME; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; TISSUE REACTION;

DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; NEOPLASMS; RAD51 RECOMBINASE; RADIATION EFFECTS; RADIATION GENETICS; RADIATION TOLERANCE; RADIATION, IONIZING; VARIATION (GENETICS);

EID: 45849118763     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860801885969     Document Type: Review

References (164)

1. Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 2006;7:165-72.
2. Agarwal S, Tafel AA, Kanaar R. DNA double-strand break repair and chromosome translocations. DNA Repair 2006;5:1075-81.
3. Iliakis G, Wang H, Perrault AR, Boecker W, Rosidi B, Windhofer F, et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004;104:14-20.
4. Costa RM, Chigancas V, Galhardo Rda S, Carvalho H, Menck CF. The eukaryotic nucleotide excision repair pathway. Biochimie 2003;85:1083-99.
5. Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003;85:1161-73.
6. Dudas A, Chovanec M. DNA double-strand break repair by homologous recombination. Mutat Res 2004;566:131-67.
7. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
8. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer 2004;90:1297-301.
9. Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005;16:163-72.
10. Nikiforov YE, Koshoffer A, Nikiforova M, Stringer A, Fagin JA. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 1999;18:6330-4.
11. Richter H, Braselmann H, Hieber I, Thomas G, Bogdanova T, Tronko N, et al. Chromosomal imbalances in post-Chernobyl thyroid tumors. Thyroid 2004;14:1061-4.
12. Saenko V, Rogounovitch T, Shimizu-Yoshida Y, Abrosimov A, Lushnikov E, Roumiantsev P, et al. Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient. Mutat Res 2003;527:81-90.
13. Rothkamm K, Huhne M, Jeggo PA, Lobrich M. Radiation-induced genomic rearrangements formed by nonhomologous end-joining of DNA double-strand breaks. Cancer Res 2001;61:3886-93.
14. Savage JR. A brief survey of aberration origin theories. Mutat Res 1998;404:139-47.
15. Chadwick KH, Leenhouts HP. The rejoining of DNA double-strand breaks and a model for the formation of chromosomal rearrangements. Int J Radiat Biol Relat Stud Phys Chem Med 1978;33:517-29.
16. Edwards AA. Modelling radiation-induced chromosome aberrations. Int J Radiat Biol 2002;78:551-8.
17. Bongarzone I, Butti MG, Fugazzola L, Pacini F, Pinchera A, Vorontsova TV, et al. Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics 1997;42:252-9.
18. Klugbauer S, Pfeiffer P, Gassenhuber H, Beimfohr C, Rabes HM. RET rearrangements in radiation-induced papillary thyroid carcinomas: High prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 2001;73:149-60.
19. Povirk LF. Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks. DNA Repair (Amst) 2006;5:1199-212.
20. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
21. Lopez-Cima MF, Gonzalez-Arriada P, Garcia-Castro L, Pascual T, Marron MG, Puente XS, et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer 2007;7:162.
22. Bau DT, Mau YC, Ding SL, Wu PE, Shen CY. DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 2007;28:1726-30.
23. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev 2004;18:1423-38.
24. Kitagawa R, Kastan MB. The ATM-dependent DNA damage signaling pathway. Cold Spring Harb Symp Quant Biol 2005;70:99-109.
25. Morrison C, Sonoda E, Takao N, Shinohara A, Yamamoto K, Takeda S. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J 2000;19:463-71.
26. Kuhne M, Riballo E, Rief N, Rothkamm K, Jeggo PA, Lobrich M. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 2004;64:500-8.
27. Auerbach AD, Veralnder PC. Disorders of DNA replication and repair. Curr Opin Pediatr 1997;9:600-16.
28. Khanna KK. Cancer risk and the ATM gene: A continuing debate. J Natl Cancer Inst 2000;92:795-802.
29. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 2000;66:494-500.
30. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003;63:3325-33.
31. Appleby JM, Barber JB, Levine E, Varley JM, Taylor AM, Stankovic T, et al. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer 1997;76:1546-9.
32. Hall EJ, Schiff PB, Hanks GE, Brenner DJ, Russo J, Chen J, et al. A preliminary report: Frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J Sci Am 1998;4:385-9.
33. Weissberg JB, Huang DD, Swift M. Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Int J Radiat Oncol Biol Phys 1998;42:1133-6.
34. Oppitz U, Bernthaler U, Schindler D, Sobeck A, Hoehn H, Platzer M, et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999;44:981-8.
35. Borgmann K, Roper B, El Awady R, Brackrock S, Bigalke M, Dork T, et al. Indicators of late normal tissue response after radiotherapy for head and neck cancer: Fibroblasts, lymphocytes, genetics, DNA repair, and chromosome aberrations. Radiother Oncol 2002;64:141-52.
36. Bremer M, Klopper K, Yamini P, Bendix-Waltes R, Dork T, Karstens JH. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: No observation of increased radiation-induced acute or late effects. Radiother Oncol 2003;69:155-60.
37. Angele S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, et al. ATM haplotypes and cellular response to DNA damage: Association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003;63:8717-25.
38. Ho AY, Fan G, Atencio DP, Green S, Formetti SC, Haffty BG, et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:677-84.
39. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006;64:776-83.
40. Andreassen CN, Alsner J, Overgaard M, Sorensen FB, Overgaard J. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006;82:577-86.
41. Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, et al. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007;68:1410-6.
42. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006;12:2545-54.
43. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 2002;52:606-13.
44. Schneider J, Philipp M, Yamini P, Dork T, Woitowitz HJ. ATM gene mutations in former uranium miners of SDAG Wismut: A pilot study. Oncol Rep 2007;17:477-82.
45. Fernet M, Hall J. Genetic biomarker of therapeutic radiation sensitivity. DNA Repair (Amst) 2004;3:1237-43.
46. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999;68:419-23.
47. Angele S, Falconer A, Edwards SM, Dork T, Bremer M, Moullan N, et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 2004;91:783-7.
48. Gutierrez-Enriquez S, Ferenet M, Dork T, Bremer M, Lauge A, Stoppa-Lyonnet D, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosome Cancer 2004;40:109-19.
49. Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 2002;99:925-30.
50. Smith GC, Cary RB, Lakin ND, Hann BC, Teo SH, Chen DJ, et al. Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM. Proc Natl Acad Sci USA 1999;96:11134-9.
51. Paull TT, Lee JH. The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 2005;4:737-40.
52. You Z, Chahwan C, Bailis J, Hunter T, Russell P. ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1. Mol Cell Biol 2005;25:5363-79.
53. Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD) - its clinical presentation and molecular basis. DNA Repair (Amst) 2004;3:1219-25.
54. Delia D, Piane M, Buscemi G, Savio C, Palmeri S, Lulli P, et al. MRE11 mutations and impaired ATM-dependent responses in an Italian family with ataxia-telangiectasia-like disorder. Hum Mol Genet 2004;13:2155-63.
55. Fernet M, Gribaa M, Salih MA, Seidahmed MZ, Hall J, Koenig M. Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder. Hum Mol Genet 2005;14:307-18.
56. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene 2006;25:5906-11.
57. Kim NG, Choi YR, Baek MJ, Kim YH, Kang H, Kim NK, et al. Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability. Cancer Res 2001;61:36-8.
58. Giannini G, Ristori E, Cerionoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-54.
59. Koh KH, Kang HJ, Li LS, Kim NG, You KT, Yang E, et al. Impaired nonhomologous end-joining in mismatch repair-deficient colon carcinomas. Lab Invest 2005;85:1130-8.
60. Lefevre SH, Coquelle A, Gonin-Laurent N, Cor A, Vogt N, Chauveninc L, et al. Non-homologous end-joining genes are not inactivated in human radiation-induced sarcomas with genomic instability. J Radiat Res (Tokyo) 2005;46:225-31.
61. Diqweed M, Sperling K. Nijmegen breakage syndrome: Clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004;3:1207-17.
62. Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masoic B, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004;64:1215-9.
63. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 2004;111:67-71.
64. Steffen J, Nowakowska D, Niwinska A, Kluska A, Piatkowska M, Wiesnewska A, et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 2006;119:472-5.
65. Varon R, Reis A, Henze G, von Einsiedel HG, Sperling K, Seeger K. Mutations in the Nijmegen breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 2001;61:3570-2.
66. Kobayashi J, Tauchi H, Sakamoto S, Nakamura A, Morishima K, Matsuura S. NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain. Curr Biol 2002;12:1846-51.
67. Maser RS, Zinkel R, Petrini JH. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat Genet 2001;27:417-21.
68. Kruger L, Demuth I, Naitzel H, Varon R, Sperling K, Chrzanowska KH, et al. Cancer incidence in Nijmegen breakage syndrome is modulated by the amount of a variant NBS protein. Carcinogenesis 2007;28:107-11.
69. Seemanova E, Jarolim P, Varon R, Pelz J, Sperling K. Cancer risk in NBS heterozygotes from the Czech Republic. Am J Hum Genet 2002;71 (Suppl):238A.
70. Medina PP, Ahrendt SA, Pollan M, Fernandez P, Sidransky D, Sanchez-Cespedes M. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. Cancer Epidemiol Biomarker Prev 2003;12:699-704.
71. Lan Q, Shen M, Berndt SI, Bonner MR, He X, Yeager M, et al. Smoky coal exposure, NBS1 polymorphisms, p53 protein accumulation, and lung cancer risk in Xuan Wei, China. Lung Cancer 2005;49:317-23.
72. Ryk C, Kumar R, Thirumaran RK, Hou SM. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer 2006;54:285-92.
73. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006;27:560-7.
74. Millikan RC, Player JS, Decotret AR, Tse CK, Keku T. Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk. Cancer Epidemiol Biomarker Prev 2005;14:2326-34.
75. Popanda O, Tan XL, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, et al. Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol Biomerker Prev 2006;15:2048-50.
76. Mohrenweiser H, Wilson D, Jones I. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003;526:93-125.
77. Thaker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett 2005;219:125-35.
78. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001;10:955-60.
79. Hasselbach L, Haase S, Fischer D, Kolberg HC, Sturzbecher HW. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol 2005;26:589-98.
80. Levi-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinets L, et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 2001;98:3232-6.
81. Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 2004;90:2002-5.
82. Webb PM, Hopper JL, Newman B, Chen X, Kelemen L, Giles GG, et al. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:319-23.
83. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004;10:2675-80.
84. Jawad M, Seedhouse CH, Russell N, Plumb M. Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood 2006;108:3916-8.
85. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression. Cancer Res 2004;64:8526-33.
86. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002;62:219-25.
87. Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in mammals. Acta Med Okayama 2005;59:1-9.
88. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 2001;21:2858-66.
89. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002;11:1399-407.
90. Danoy P, Sonoda E, Lathrop M, Takeda S, Matsuda F. A naturally occurring genetic variant of human XRCC2 (R188H) confers increased resistance to cisplatin-induced DNA damage. Biochem Biophys Res Commun 2007;352:763-8.
91. Han J, Hankinson SE, Ranu H, De Vivo I, Hunter DJ. Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study. Carcinogenesis 2004;25:189-95.
92. Garcia-Glosas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: Two population-based studies in USA and Poland, and meta-analyses. Hum Genet 2006;119:376-88.
93. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 2005;117:611-8.
94. Sadetzki S, Flint-Richter P, Starinsky S, Novikov I, Lerman Y, Goldman B, et al. Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarker Prev 2005;14:969-76.
95. Hu JJ, Smith RR, Miller MS, Monhrenwaiser HW, Golden A, Case LD. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001;22:917-22.
96. Hu JJ, Smith TR, Miller MS, Lohman K, Case LD. Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ Mol Mutagen 2002;39:208-15.
97. Andreassen CM, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005;75:18-21.
98. De Ruyck K, Van Eijkeren M, Claes K, Morthier R, De Paepe A, Vral A, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005;62:1140-9.
99. Andreassen CM, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003;69:127-35.
100. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003;111:1843-50.
101. Aka P, Mateuca R, Buchet IP, Thierens H, Kirsch-Volders M. Are genetic polymorphisms in OGG1, XRCC1 and XRCC3 genes predictive for the DNA strand break repair phenotype and genotoxicity in workers exposed to low dose ionising radiations? Mutat Res 2004;556:169-71.
102. Winsley SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000;60:5612-6.
103. Thirumaran RK, Bermejo JL, Rudnaj P, Gurzau E, Koppova K, Goessler W, et al. Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis 2006;27:1676-81.
104. Sturgis EM, Zhao C, Zheng R, Wei Q. Radiation response genotype and risk of differentiated thyroid cancer: A case-control analysis. Laryngoscope 2005;115:938-45.
105. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001;92:562-7.
106. Araujo FD, Pierce AJ, Starkl JM, Jasin M. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002;21:4176-80.
107. Price EA, Bourne SL, Radbourne R, Lawton PA, Lamerdin J, Thompson LH, et al. Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet 1997;23:237-47.
108. De Ruyck K, Widing CS, Van Eijkeren M, Morthier R, Tawn EJ, Thierens H. Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: Association with late clinical radiosensitivity and cancer incidence. Radiat Res 2005;164:237-44.
109. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
110. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
111. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999;285:747-50.
112. Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL, et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002;420:287-93.
113. Yu DS, Sonoda E, Takeda S, Huang CL, Pellegrini L, Blundell TL, et al. Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol Cell 2003;12:1029-41.
114. Honrado E, Beniztez J, Palacios J. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mol Pathol 2005;18:1305-20.
115. Gaffney DK, Brohet RM, Lewis CM, Holden JA, Byus SS, Neuhausen SL, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998;47:129-36.
116. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360-9.
117. Leong T, Whitty J, Keilar M, Mifsud S, Ramsay J, Birrel G, et al. Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. Int J Radiat Oncol Biol Phys 2000;48:959-65.
118. Buchholz TA, Wu X, Hussain A, Tucker SL, Mills GB, Haffty B, et al. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer 2002;97:557-61.
119. Nieuewehhuis B, Van Assen-Bolt AJ, Van Waarde-Verhagen MA, Sijmons RH, Van der Hout AH, Bauch T, et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol 2002;78:285-95.
120. Trenz K, Rothfuss A, Schutz P, Speit G. Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation. Mutat Res 2002;500:89-96.
121. Trenz K, Schutz P, Speit G. Radiosensitivity of lymphoblastoid cell lines with a heterozygous BRCA1 mutation is not detected by the comet assay and pulsed field gel electrophoresis. Mutagenesis 2005;20:131-7.
122. Baeyens A, Thierens H, Claes K, Poppe B, de Ridder L, Vral A. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int J Radiat Biol 2004;80:745-56.
123. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304-11.
124. Wang H, Zeng ZC, Bui TA, DiBiase SJ, Qin W, Xia F, et al. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. Cancer Res 2001;61:270-7.
125. Zhang C, Naftalis E, Euhus D. Carcinogen-induced DNA double strand break repair in sporadic breast cancer. J Surg Res 2006;135:120-8.
126. Chan DW, Chen BP, Prithivarajsingh S, Kurimasa A, Story MD, Qin J, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 2002;16:2333-8.
127. Collis SJ, De Weese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 2005;24:949-61.
128. Lieber MR, Ma Y, Pannicke U, Schwartz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4:712-20.
129. Virsik-Kopp P, Rave-Frank M, Hofman-Huther H, Schmidberger H. Role of DNA-PK in the process of aberration formation as studied in irradiated human glioblastoma cell lines M059K and M059J. Int J Radiat Biol 2003;79:61-8.
130. Hoppe BS, Jensen RB, Kirchgessner CU. Complementation of the radiosensitive M059J cell line. Radiat Res 2000;153:125-30.
131. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002;62:6400-4.
132. Collis SJ, Swartz MJ, Nelson WG, De Weese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550-4.
133. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006;16:51-8.
134. Zhang Y, Zhou J, Cao X, Zhang Q, Lim CU, Bailey SM, et al. Partial deficiency of DNA-PKcs increases ionizing radiation-induced mutagenesis and telomere instability in human cells. Cancer Lett 2007;250:63-73.
135. Yu Y, Okayashi R, Weil MM, Silver A, McCarthy M, Zabriskie R, et al. Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res 2001;61:1820-4.
136. Mori N, Matsumoto Y, Okumoto M, Suzuki N, Yamate J. Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis. Oncogene 2001;20:3609-19.
137. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002;62:3052-7.
138. Fu YP, Ju JC, Cheng TC, Lou MA, Hsu GC, Wu CY, et al. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res 2003;63:2440-6.
139. Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M, et al. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature 1997;388:492-5.
140. Drouet J, Delteil C, Lefrancois J, Concannon P, Salles B, Calsou P. DNA-dependent protein kinase and XRCC4-DNA ligase IV mobilization in the cell in response to DNA double strand breaks. J Biol Chem 2005;280:7060-9.
141. Mori M, Itsukaichi H, Nakamura A, Sato K. Molecular characterization of ionizing radiation-hypersensitive mutant M10 cells. Mutat Res 2001;487:85-92.
142. Itsukaichi H, Mori M, Nakamura A, Sato K. Identification of a new G-to-A transition mutation at nucleotide position 129 of the Xrcc4 gene in ionizing radiation-hypersensitive mutant LX830 cells. J Radiat Res (Tokyo) 2003;44:353-8.
143. van Heemst D, Brugmans L, Verkaik NS, van Gent DC. End-joining of blunt DNA double-strand breaks in mammalian fibroblasts is precise and requires DNA-PK and XRCC4. DNA Repair (Amst) 2004;3:43-50.
144. Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B, et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 1999;9:699-702.
145. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair (Amst) 2004;3:1227-35.
146. Buck D, Moshous D, de Chasseval R, Ma Y, le Deist F, Cayazzana-Calvo M, et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 2006;36:224-35.
147. Enders A, Fisch P, Schwarz K, Duffner U, Pannicke U, Nikopoulos E, et al. Severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J Immunol 2006;176:5060-8.
148. Wilding CS, Relton CL, Rees GS, Tarone RE, Whitehouse CA, Tawn EJ. DNA repair gene polymorphisms in relation to chromosome aberration frequencies in retired radiation workers. Mutat Res 2005;570:137-45.
149. Ramadan K, Shevelev I, Hubscher U. The DNA-polymerase-X family: Controllers of DNA quality? Nat Rev Mol Cell Biol 2004;5:1038-43.
150. Mahajan KN, Nick McElhinny SA, Mitchell BS, Ramsden DA. Association of DNA polymerase mu (pol mu) with Ku and ligase IV: Role for pol mu in end-joining double-strand break repair. Mol Cell Biol 2002;22:5194-202.
151. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002;108:781-94.
152. Zhang X, Succi J, Feng Z, Prithiyirajsingh S, Story MD, Legerski RJ. Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol 2004;24:9207-20.
153. Soubeyrand S, Pope L, De Chasseval R, Gosselin D, Dong F, de Villartay JP, et al. Artemis phosphorylated by DNA-dependent protein kinase associates preferentially with discrete regions of chromatin. J Mol Biol 2006;358:1200-11.
154. Darroudi F, Wiegant W, Meijers M, Friedl AA, van der Burg, Fomina J, et al. Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle. Mutat Res 2007;615:111-24.
155. Rooney S, Alt FW, Lombard D, Whitlow S, Eckersdorff M, Fleming J, et al. Defective DNA repair and increased genomic instability in Artemis-deficient murine cells. J Exp Med 2003;197:553-65.
156. Musio A, Marrella V, Sobacchi C, Rucci F, Fariselli L, Giliani S, et al. Damaging-agent sensitivity of Artemis-deficient cell lines. Eur J Immunol 2005;35:1250-6.
157. Li L, Moshous D, Zhou Y, Wang J, Xie G, Satido E, et al. A founder mutation in Artemis, a SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002;168:6323-9.
158. Rooney S, Sekiguchi J, Zhu C, Cheng HL, Manis J, Whitlow S, et al. Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. Mol Cell 2002;10:1379-90.
159. Moshous D, Pannetier C, Chasseval RR, Deilst FF, Cavazzana-Calvo M, Romana S, et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 2003;111:381-7.
160. Ege M, Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR, et al. Omenn syndrome due to ARTEMIS mutations. Blood 2005;105:4179-86.
161. Iwakawa M, Imai T, Harada Y, Ban S, Michikawa Y-I, Saegusa K, et al. Nippon Acta Radiol 2002;62:484-9.
162. West CM, McKay MJ, Holscher T, Baumann M, Stratford IJ, Bristow RG, et al. Molecular markers predicting radiotherapy response. Report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 2005;62:1264-73.
163. Baumann M, Holscher T, Begg AC. Towards genetic prediction of radiation
164. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, et al. Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. Int J Radiat Oncol Biol Phys 2006;65:646-53.